{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T20:40:15Z","timestamp":1739220015455,"version":"3.37.0"},"reference-count":60,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,2,7]]},"abstract":"<jats:p>The term metabolic dysfunction\u2013associated fatty liver disease (MAFLD) has been proposed based on a redefinition of the nonalcoholic fatty liver disease (NAFLD) criteria. Our study aimed to address the knowledge gap by comparing the diagnostic accuracy of MAFLD and NAFLD criteria in identifying significant fibrosis among patients with hepatic steatosis. A cross-sectional study was conducted on 2626 patients with hepatic steatosis treated at Beijing Ditan Hospital between January 2009 and December 2022. Patients with viral hepatitis were excluded. Significant fibrosis was defined as a Meta-analysis of Histological Data in Viral Hepatitis (METAVIR) score <jats:italic toggle=\"yes\">F<\/jats:italic>\u2005\u2265\u20052. MAFLD and NAFLD were diagnosed in 478 and 428 patients, respectively. Clinicopathological characteristics were compared between the MAFLD+ NAFLD\u2013 group (patients who met the criteria for MAFLD but not NAFLD) and MAFLD\u2013 NAFLD+ group (patients who met the criteria for NAFLD but not MAFLD). A total of 743 patients with histologically verified hepatic steatosis were analyzed. The MAFLD+ NAFLD\u2013 group comprised 163 (21.9%) and the MAFLD\u2013 NAFLD+ group comprised 113 (15.2%) patients. Patients in the MAFLD+ NAFLD\u2013 group were older and more likely to be male and had higher body mass index and liver stiffness levels than those in the MAFLD\u2013 NAFLD+ group. The prevalence of significant fibrosis was higher in the MAFLD+ NAFLD\u2013 group than in the MAFLD\u2013 NAFLD+ group (43.6% vs 15.9%, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.001). The MAFLD criteria may be a better indicator of fibrosis than the NAFLD criteria. Fibrosis in patients with MAFLD can be determined by metabolic disorders, not excessive alcohol consumption.<\/jats:p>","DOI":"10.1097\/md.0000000000041455","type":"journal-article","created":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T20:00:34Z","timestamp":1739217634000},"page":"e41455","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Metabolic dysfunction\u2013associated fatty liver disease indicates more hepatic fibrosis than nonalcoholic fatty liver disease"],"prefix":"10.1097","volume":"104","author":[{"given":"Shan","family":"Hong","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Beijing Ditan Hospital, Capital Medical University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zifan","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Applied Information, Tomsk State University, Tomsk, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiwei","family":"Hao","sequence":"additional","affiliation":[{"name":"Department of Medical Records and Statistics, Beijing Ditan Hospital, Capital Medical University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Pathology, Beijing Ditan Hospital, Capital Medical University, Beijing, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongshan","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Beijing Ditan Hospital, Capital Medical University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250210","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/dom.14521","article-title":"A clinical overview of non-alcoholic fatty liver disease: a guide to diagnosis, the clinical features, and complications\u2014what the non-specialist needs to know.","volume":"24","author":"Muthiah","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"R2-20250210","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s12072-020-10094-2","article-title":"The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease.","volume":"14","author":"Eslam","year":"2020","journal-title":"Hepatol Int"},{"key":"R3-20250210","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.3390\/ijerph19042096","article-title":"Prevalence and risk factors of metabolic-associated fatty liver disease among 73,566 individuals in Beijing, China.","volume":"19","author":"Yuan","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"R4-20250210","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/j.cgh.2020.10.046","article-title":"Impact of the new definition of metabolic associated fatty liver disease on the epidemiology of the disease.","volume":"19","author":"Wong","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R5-20250210","doi-asserted-by":"crossref","first-page":"865","DOI":"10.5152\/tjg.2019.18045","article-title":"Non-alcoholic fatty liver disease: a growing public health problem in Turkey.","volume":"30","author":"Kaya","year":"2019","journal-title":"Turk J Gastroenterol"},{"key":"R6-20250210","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/MOG.0000000000000823","article-title":"Metabolic dysfunction-associated fatty liver disease: a year in review.","volume":"38","author":"Alharthi","year":"2022","journal-title":"Curr Opin Gastroenterol"},{"key":"R7-20250210","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/hep.31173","article-title":"Changes in the global burden of chronic liver diseases from 2012 to 2017: the growing impact of NAFLD.","volume":"72","author":"Paik","year":"2020","journal-title":"Hepatology"},{"key":"R8-20250210","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrgastro.2013.41","article-title":"Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis.","volume":"10","author":"Anstee","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R9-20250210","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases.","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"R10-20250210","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors, and prevention.","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R11-20250210","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1053\/j.gastro.2019.05.064","article-title":"Toward more accurate nomenclature for fatty liver diseases.","volume":"157","author":"Eslam","year":"2019","journal-title":"Gastroenterology"},{"key":"R12-20250210","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S2468-1253(19)30342-5","article-title":"Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission.","volume":"5","author":"Sarin","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R13-20250210","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease.","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"key":"R14-20250210","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature.","volume":"79","author":"Rinella","year":"2023","journal-title":"J Hepatol"},{"key":"R15-20250210","doi-asserted-by":"crossref","first-page":"102420","DOI":"10.1016\/j.jceh.2024.102420","article-title":"Comparison of NAFLD, MAFLD, and MASLD prevalence and clinical characteristics in Asia adults.","volume":"15","author":"Huang","year":"2025","journal-title":"J Clin Exp Hepatol"},{"key":"R16-20250210","doi-asserted-by":"crossref","first-page":"254","DOI":"10.14309\/ajg.0000000000001054","article-title":"Role of noninvasive tests in clinical gastroenterology practices to identify patients with nonalcoholic steatohepatitis at high risk of adverse outcomes: expert panel recommendations.","volume":"116","author":"Younossi","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"R17-20250210","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/apt.12569","article-title":"Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease\u2014the role of transient elastography and plasma cytokeratin-18 fragments.","volume":"39","author":"Kwok","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"R18-20250210","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/hep.27368","article-title":"The fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up.","volume":"61","author":"Ekstedt","year":"2015","journal-title":"Hepatology"},{"key":"R19-20250210","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1053\/j.gastro.2020.01.043","article-title":"Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis.","volume":"158","author":"Taylor","year":"2020","journal-title":"Gastroenterology"},{"key":"R20-20250210","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.jhep.2017.07.027","article-title":"Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD.","volume":"67","author":"Hagstr\u00f6m","year":"2017","journal-title":"J Hepatol"},{"key":"R21-20250210","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease.","volume":"149","author":"Angulo","year":"2015","journal-title":"Gastroenterology"},{"key":"R22-20250210","doi-asserted-by":"crossref","first-page":"875","DOI":"10.3390\/cells9040875","article-title":"Liver fibrosis: mechanistic concepts and therapeutic perspectives.","volume":"9","author":"Roehlen","year":"2020","journal-title":"Cells"},{"key":"R23-20250210","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/hep.28368","article-title":"Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: a multicenter prospective study.","volume":"63","author":"Piscaglia","year":"2016","journal-title":"Hepatology"},{"key":"R24-20250210","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.cgh.2014.08.013","article-title":"Temporal trends of nonalcoholic fatty liver disease-related hepatocellular carcinoma in the veteran affairs population.","volume":"13","author":"Mittal","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R25-20250210","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1053\/j.gastro.2018.04.034","article-title":"Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study.","volume":"155","author":"Vilar-Gomez","year":"2018","journal-title":"Gastroenterology"},{"key":"R26-20250210","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s00535-017-1415-1","article-title":"Current and future pharmacological therapies for NAFLD\/NASH.","volume":"53","author":"Sumida","year":"2018","journal-title":"J Gastroenterol"},{"key":"R27-20250210","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1111\/liv.14675","article-title":"MAFLD identifies patients with significant hepatic fibrosis better than NAFLD.","volume":"40","author":"Yamamura","year":"2020","journal-title":"Liver Int"},{"key":"R28-20250210","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1016\/j.cgh.2021.05.029","article-title":"Differential clinical characteristics and mortality outcomes in persons with NAFLD and\/or MAFLD.","volume":"19","author":"Nguyen","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R29-20250210","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/hepr.13737","article-title":"Comparison of diagnostic performance between FIB-4 and NFS in metabolic-associated fatty liver disease era.","volume":"52","author":"Park","year":"2022","journal-title":"Hepatol Res"},{"key":"R30-20250210","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1186\/s12876-022-02576-4","article-title":"A comparison of NAFLD and MAFLD diagnostic criteria in contemporary urban healthy adults in China: a cross-sectional study.","volume":"22","author":"Liu","year":"2022","journal-title":"BMC Gastroenterol"},{"key":"R31-20250210","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1111\/liv.15259","article-title":"Prevalence of advanced hepatic fibrosis and comorbidity in metabolic dysfunction-associated fatty liver disease in Korea.","volume":"42","author":"Kim","year":"2022","journal-title":"Liver Int"},{"key":"R32-20250210","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.dld.2021.05.014","article-title":"MAFLD vs NAFLD: where are we?","volume":"53","author":"Mantovani","year":"2021","journal-title":"Dig Liver Dis"},{"key":"R33-20250210","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1002\/hep.32499","article-title":"Are there outcome differences between NAFLD and metabolic-associated fatty liver disease?","volume":"76","author":"Younossi","year":"2022","journal-title":"Hepatology"},{"key":"R34-20250210","doi-asserted-by":"crossref","first-page":"4","DOI":"10.14218\/JCTH.2021.00485","article-title":"MAFLD not NAFLD is associated with impairment of health-related quality of life.","volume":"10","author":"Attia","year":"2022","journal-title":"J Clin Transl Hepatol"},{"key":"R35-20250210","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/liv.15139","article-title":"Systematically comparing epidemiological and clinical features of MAFLD and NAFLD by meta-analysis: focusing on the non-overlap groups.","volume":"42","author":"Ayada","year":"2022","journal-title":"Liver Int"},{"key":"R36-20250210","doi-asserted-by":"crossref","first-page":"e745","DOI":"10.1210\/clinem\/dgab644","article-title":"Metabolic dysfunction-associated fatty liver disease and mortality among Chinese adults: a prospective cohort study.","volume":"107","author":"Wang","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"R37-20250210","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.2147\/DMSO.S316096","article-title":"MAFLD criteria may overlook a subtype of patient with steatohepatitis and significant fibrosis.","volume":"14","author":"Huang","year":"2021","journal-title":"Diabetes Metab Syndr Obes"},{"key":"R38-20250210","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement.","volume":"73","author":"Eslam","year":"2020","journal-title":"J Hepatol"},{"key":"R39-20250210","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease.","volume":"64","year":"2016","journal-title":"J Hepatol"},{"key":"R40-20250210","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/hep.510240201","article-title":"An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group.","volume":"24","author":"Bedossa","year":"1996","journal-title":"Hepatology"},{"key":"R41-20250210","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jhep.2019.04.019","article-title":"Report on the AASLD\/EASL joint workshop on clinical trial endpoints in NAFLD.","volume":"71","author":"Rinella","year":"2019","journal-title":"J Hepatol"},{"key":"R42-20250210","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease.","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"R43-20250210","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1053\/j.gastro.2016.03.008","article-title":"Biopsy and noninvasive methods to assess progression of nonalcoholic fatty liver disease.","volume":"150","author":"Bedossa","year":"2016","journal-title":"Gastroenterology"},{"key":"R44-20250210","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1002\/hep.25993","article-title":"Determination of reliability criteria for liver stiffness evaluation by transient elastography.","volume":"57","author":"Boursier","year":"2013","journal-title":"Hepatology"},{"key":"R45-20250210","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia"},{"key":"R46-20250210","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1751-2980.2010.00476.x","article-title":"Guidelines for the diagnosis and management of non-alcoholic fatty liver disease: update 2010 guidelines for the diagnosis and management of alcoholic liver disease: update 2010: (published in Chinese on Chinese Journal of Hepatology 2010; 18: 163\u2013166).","volume":"12","author":"Fan","year":"2011","journal-title":"J Dig Dis"},{"key":"R47-20250210","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.jhep.2021.07.035","article-title":"Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States.","volume":"75","author":"Kim","year":"2021","journal-title":"J Hepatol"},{"key":"R48-20250210","doi-asserted-by":"crossref","first-page":"e0245762","DOI":"10.1371\/journal.pone.0245762","article-title":"Outcomes of NAFLD and MAFLD: results from a community-based, prospective cohort study.","volume":"16","author":"Niriella","year":"2021","journal-title":"PLoS One"},{"key":"R49-20250210","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/hep.32131","article-title":"Metabolic dysfunction-associated fatty liver disease improves detection of high liver stiffness: the Rotterdam Study.","volume":"75","author":"van Kleef","year":"2022","journal-title":"Hepatology"},{"key":"R50-20250210","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/hep.32552","article-title":"The transition from NAFLD to MAFLD: one size still does not fit all\u2014time for a tailored approach?","volume":"76","author":"van Kleef","year":"2022","journal-title":"Hepatology"},{"key":"R51-20250210","doi-asserted-by":"crossref","first-page":"693507","DOI":"10.3389\/fmed.2021.693507","article-title":"NAFLD or MAFLD: which has closer association with all-cause and cause-specific mortality?\u2014results from NHANES III.","volume":"8","author":"Huang","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"R52-20250210","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/HEP.0000000000000351","article-title":"Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes [published online ahead of print, 2023 Mar 17].","volume":"78","author":"Pennisi","year":"2023","journal-title":"Hepatology"},{"key":"R53-20250210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol Int"},{"key":"R54-20250210","doi-asserted-by":"crossref","first-page":"101589","DOI":"10.1016\/j.aohep.2024.101589","article-title":"Prevalence and risk factors of significant fibrosis in chronic hepatitis B patients with concurrent metabolic dysfunction-associated steatotic liver disease.","volume":"30","author":"Hong","year":"2024","journal-title":"Ann Hepatol"},{"key":"R55-20250210","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1002\/hep.32642","article-title":"Metabolic dysfunction-associated fatty liver disease and excessive alcohol consumption are both independent risk factors for mortality.","volume":"77","author":"van Kleef","year":"2023","journal-title":"Hepatology"},{"key":"R56-20250210","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.jhep.2021.09.002","article-title":"NAFLD vs. MAFLD\u2014it is not the name but the disease that decides the outcome in fatty liver.","volume":"76","author":"De","year":"2022","journal-title":"J Hepatol"},{"key":"R57-20250210","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/s12944-018-0865-7","article-title":"Risk of reduced platelet counts in patients with nonalcoholic fatty liver disease (NAFLD): a prospective cohort study.","volume":"17","author":"Liu","year":"2018","journal-title":"Lipids Health Dis"},{"key":"R58-20250210","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1111\/j.1572-0241.1999.01231.x","article-title":"Serum thrombopoietin levels in patients with chronic hepatitis and liver cirrhosis.","volume":"94","author":"Kawasaki","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"R59-20250210","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.jhep.2022.06.012","article-title":"Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease\u2014novel insights into cellular communication circuits.","volume":"77","author":"Peiseler","year":"2022","journal-title":"J Hepatol"},{"key":"R60-20250210","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2018.12.036","article-title":"Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease.","volume":"156","author":"Castera","year":"2019","journal-title":"Gastroenterology"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000041455","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T20:00:52Z","timestamp":1739217652000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000041455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,7]]},"references-count":60,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000041455","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,7]]}}}